Synapticure Secures $25M to Expand Platform for Neurodegenerative Diseases

Synapticure, a telemedicine company dedicated to supporting individuals and caregivers living with neurodegenerative diseases, has raised $25 million in a Series A funding round led by B Capital. New investors, including CVS Health Ventures, RA Capital Management, CommonSpirit Health, and Nexus NeuroTech Ventures, joined the round alongside existing investors Google Ventures, Rock Health Capital, and Optum Ventures.

Synapticure provides virtual care for people with neurodegenerative diseases such as ALS, Alzheimer’s, Parkinson’s, and Huntington’s disease, offering services like mental health support, genetic testing, and guidance for clinical trials. The company plans to use the funding to expand partnerships with healthcare payers and providers, advance its technology platform, accelerate clinical research, and scale its operations nationwide.

Sandra Abrevaya, cofounder and CEO of Synapticure, emphasized that the investment will enable the company to democratize care for families dealing with neurodegenerative diseases, ensuring that patients across the U.S. can receive expert, personalized care.

Founded in 2022 by Abrevaya and her husband, Brian Wallach, an ALS patient and former U.S. attorney, Synapticure launched with $6 million in seed funding from Google Ventures. The company recently partnered with Pearl Health to offer personalized support to Medicare patients with dementia through the CMS GUIDE program. Earlier, Synapticure also collaborated with the ALS Association to provide its telehealth platform as a supplement to in-person care at ALS-certified treatment centers.